Form 4: Assembly Biosciences Director Consylman Receives Stock Options

Director Gina Consylman was granted stock options for 2,750 shares of Assembly Biosciences, Inc. (ASMB) on May 29, 2024.

Summary

• Gina Consylman, a director of Assembly Biosciences, Inc., received stock options to purchase 2,750 shares of common stock on May 29, 2024.
• The exercise price of these options is $15.06 per share.
• The options vest on the earlier of May 29, 2025, or the date of the Issuer's 2025 annual meeting of stockholders, assuming continuous service.
• The options expire on May 29, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates confidence in the company's future, but doesn't provide any specific positive or negative news.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical.
• The number of shares granted is dependent on the size and stage of the company, as well as the director's role and responsibilities.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates